Shandong Cheung Tak Bio Wu Xiaohong: The Tianchi Exchange Listing is only the beginning

Business News Agency February 20 News 8 years, from a little-known small plant to a listed company, registered capital increased from 500,000 yuan to 35 million yuan, the city's Cheung Tak Biological Co., Ltd. realized gorgeous Turn around.

On December 26th, the Tianjin Equity Exchange rang out with a buzzing sound, marking the official listing of Shandong Xiangde Biological Co., Ltd. This is the second company listed in the OTC market in the city.

To achieve 70 times the expansion of high-quality assets in 8 years is the basis for listing transactions. Who can believe that only 13 employees and a registered capital of only 500,000 yuan in a rural private enterprise in the past 8 years, developed into an area of ​​150 acres, with a registered capital of 35 million Yuan's joint-stock companies have realized the myth of increasing capital by 70 times. When Wu Xiaohong, the company's chairman, introduced the development of the company, his words were full of confidence and determination.

Cheung Tak Biotechnology Co., Ltd. was established in 2003 as a result of the overall change of Runfeng Biotechnology Co., Ltd. Wu Xiaohong said that the success of the listing transaction was first of all based on the company's high quality products.

"At the time, only 500,000 yuan had been set up in the hands. Be careful with each step. There are more than a dozen people in your own family to eat." Wu Xiaohong said: "You can't eat big fat people at one go. At the beginning of its creation.” Therefore, in order to avoid the risk of triangular debt, the company never wrote off the credit, but rather focused on quality. Due to the high quality of the products, orders were rushed and funds gradually filled.

In the face of peer competition, under the premise of ensuring quality, all links must be carefully planned to reduce costs. Through open tendering, the company determined a single fixed raw material supplier and logistics company with high quality and good reputation. Due to the large amount of goods and the low unit cost, the price will be reduced. Only one year of logistics and transportation will save nearly one million yuan each year. The sodium alkoxide, magnesium alkoxide and potassium alkoxide series products produced by the company quickly occupy the market due to high quality and low price, and are sold overseas. The quality assets continue to grow, and the company enters a sound development.

In June of this year, the company invested 150 million yuan in new production of 100 tons of pyrrolinone and an annual output of 5,000 tons of di-tert-butyl peroxide project. The project can realize annual sales income of 270 million yuan and profits and taxes of 70 million yuan. At present, the company’s new 6-tier technology R&D building will be put into use at the end of 2012.

"Marriage" Universities to improve their competitiveness to ensure the healthy development of science and technology is an inexhaustible motive force for the development of the enterprise. At the beginning of the establishment of the company, standardized laboratories were set up to recruit students from related majors to enrich them. In the process of company development, they affiliated with scientific research units and established long-term research and development cooperation relations with Nankai University and China Jiahua Group, and established laboratories at Nankai University. Through collaboration and scientific research, the company improved its production process to increase its profitability by 15%, and jointly researched and developed more than 20 pharmaceutical raw material intermediates, 8 of which filled domestic gaps and 3 led the world.

The company is not only a professional ** intermediate producer, but also a production and export base, in which the sales volume of single product sodium methoxide ranks second in the country. Today, the company has 17 sets of advanced production lines and modern gas chromatography inspection equipment, annual production capacity of 20,000 tons of sodium methanol, in addition to the best-selling domestic market, the main products have passed the EU Reach certification, direct exports to the United States, Japan, the United Kingdom and other developed Countries and Southeast Asia, Middle East.

While actively introducing talents, the company takes out millions of yuan each year to organize company employees to visit and study in other places in phases, and invites experts to come to the company to teach. At present, the company has 15% or more of undergraduate employees, 40% or more of specialists, and 30 employees in a vocational college or university in Jinan.

Listing trading is only the beginning of the realization of the listing of the main board is the goal of talking about the day exchange listed transactions, Wu Xiaohong can not hide the joy.

She explained that the company has always been developing in the high-tech field, with strong stamina and good prospects, and there is no record of bad credit. The company took the opportunity of this listing to fully regulate the internal management of the company and improve its internal quality. Accountants and lawyers conduct compliance audits of financial conditions. Therefore, it passed the rigorous review of the jury committee in just two months. The defense will be successfully prepared and won unanimous approval by eight experts in less than 20 minutes. On the first day of the transaction, Cheung Tak biological targeted 4.76 million shares of private equity, 1.05 yuan per share, raised funds of 5 million yuan, and added capital of 35 million yuan.

The listing transaction enables the company to use the equity to lower costs while at the same time allowing the management level of the company to rise to a new stage. The listed companies accept the annual evaluation report on the company's “growth, corporate governance and independent innovation” by the evaluation team of the stock exchange, and receive special training in corporate finance, marketing strategy, and human resources management to guide and help the company grow healthily. Wu Xiaohong said that we are confident that through this listed trading platform, we will continue to improve the company's management structure, enhance the core competitive ability, achieve rapid growth, and ultimately achieve the listing of the main board.